Holen Sie sich die Stockscreener-App
6.84
2.29%
-0.16
Schlusskurs vom Vortag:
$7.00
Offen:
$7
24-Stunden-Volumen:
442.81K
Relative Volume:
0.71
Marktkapitalisierung:
$707.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.39M
KGV:
-3.8791
EPS:
-1.7633
Netto-Cashflow:
$-91.64M
1W Leistung:
-11.63%
1M Leistung:
+11.76%
6M Leistung:
+34.38%
1J Leistung:
+1.03%
1-Tages-Spanne:
$6.64
$7.30
1-Wochen-Bereich:
$6.64
$7.87
52-Wochen-Spanne:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Firmenname
Aura Biosciences Inc
Sektor
Branche
Telefon
(617)500-8864
Adresse
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.84 | 707.51M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-26 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-05-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-07-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Form 4 Aura Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant - Stock Titan
Aura Biosciences (NASDAQ: AURA) files initial Form 3 for director Jeremy Bender - Stock Titan
Aura Biosciences Announces Appointment of Jer - Moomoo
Aura Biosciences strengthens board with new independent director - TipRanks
Aura Biosciences Appoints Jeremy Bender to Board as Bel-Sar Advances Toward Potential Regulatory Approval for Choroidal Melanoma 1 – Minichart - Minichart
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors - The Manila Times
Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director - Stock Titan
Aura Biosciences Insiders Made A Wise Decision By Selling US$939k Worth Of Stock - 富途牛牛
The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Stock Climbs on Pipeline ProgressSpecial Dividend Alert - dars.gov.et
More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k - simplywall.st
Executive at Aura Biosciences (AURA) receives 14,858 RSUs - Stock Titan
Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
AURA | Aura Biosciences, Inc. Common Executive Compensation - Quiver Quantitative
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com - Investing.com Nigeria
Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak - Stock Titan
Aura Biosciences Inc Actuals & Estimates (BOATS:AURA) - TradingView
Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA) - TradingView
AURA Forecast — Price Target — Prediction for 2027 - TradingView
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones - Stock Traders Daily
Aura Biosciences Inc (AURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Inc (AURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak - Stock Titan
Aura Biosciences Inc (AURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aura Biosciences Inc (AURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move - TipRanks
Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares - Stock Titan
Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding - Stock Titan
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences (AURA) Gains 3% as Shares Bounce from SupportNHNL Ratio - newsline.com
Aura Biosciences, Inc. 8-K Filing Details for June 11, 2026: Emerging Growth Status and Shareholder Vote Submission 1821 – Minichart - Minichart
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
Aura Biosciences Announces Results of 2026 Annual Meeting - TipRanks
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor - Stock Titan
Aura Biosciences Inc. Q1 2026 Earnings: Wider-than-Expected Loss Marks Early-Stage Pipeline Progress - newsline.com
Aura Biosciences gears up for Bel-Sar filing as pivotal eye cancer trial advances - MSN
AURA - Finviz
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
Aura Biosciences completes phase 3 enrollment for eye cancer drug By Investing.com - Investing.com India
Finanzdaten der Aura Biosciences Inc-Aktie (AURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):